Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.

Medical cannabis has a high discontinuation rate among patients with chronic musculoskeletal pain, particularly in the first ...

Progression-free survival and overall survival were significantly greater in the combination therapy group compared to ...

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...

In this retrospective cohort study, the proportion of chemotherapy episodes delivered by oncology subspecialists in the ...